GLPwatch
Papers (12034)
Page 119 of 201, ranked by citation count.
- Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.
- Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
- A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol.
- The Modified Exenatide Microspheres: PLGA-PEG-PLGA Gel and Zinc-Exenatide Complex Synergistically Reduce Burst Release and Shorten Platform Stage.
- Tirzepatide-Associated Colonic Ischemia.
- Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations.
- Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.
- The need to personalise approaches for the prevention and management of obesity.
- Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.
- Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis.
- Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis.
- Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.
- The efficacy of liraglutide combined with intragastric balloon on weight loss.
- Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
- Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects.
- GLP-1 receptor agonists and alcohol use disorder: a systematic review.
- Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
- Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.
- Treating bile acid diarrhoea with liraglutide.
- Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
- Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
- Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
- Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.
- Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial.
- Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
- Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
- Exacerbation of atrial fibrillation related to dulaglutide use.
- Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Efficacy and Adverse Events.
- Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.
- Is exenatide the next big thing in Parkinson's disease?
- Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.
- Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
- Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.
- Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.
- Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.
- Unravelling the mechanisms of a protein refolding process based on the association of detergents and co-solvents.
- The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide.
- GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review.
- Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.
- [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus<sup>®</sup> tablets), an oral GLP-1 receptor agonist].
- Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.
- Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
- Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
- Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
- Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons.
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
- Mitigation of Hearing Damage With Liraglutide Treatment in Chinchillas After Repeated Blast Exposures at Mild-TBI.
- The GLP-1 agonist, exendin-4, stimulates LH secretion in female sheep.
- As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.
- Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins.
- Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
- Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.